Sagar Lonial - 11 Sep 2025 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Reporting relationship: Director
Issuer ticker: TGTX
Reported as of: 11 Sep 2025
Net transaction value: -$672,268
SEC form: 4
Accepted by SEC: 12 Sep 2025, 16:42:45 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sagar Lonial

Key filing fact

Sagar Lonial filed Form 4 for TG THERAPEUTICS, INC. (TGTX) on 12 Sep 2025.

Key facts

This page summarizes Sagar Lonial's Form 4 filing for TG THERAPEUTICS, INC. (TGTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Sep 2025, 16:42.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: -$672,268.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816609 Primary reporting owner

Lonial Sagar

Relationship: Director
Address: 3020 CARRINGTON MILL BLVD, SUITE 475, MORRISVILLE
Signature: /s/ Sagar Lonial
Signature date: 12 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TGTX transaction

Common Stock

Sale

Transaction value: $672,268
Shares: -20,852
Change %: -18%
Price: $32.24
Shares after: 94,061
Date: 11 Sep 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares were sold by the Company's restricted stock administrator in order to satisfy the Reporting Person's income tax obligations.

Footnote F2

Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $32.22 to $32.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Includes shares of restricted Common Stock, which vest over various time periods.